BCYCHIGH SIGNALFINANCIAL10-K

BCYC shows concerning financial deterioration with operating cash flow declining 51.6% to -$249.7M while cash reserves dropped 28.6% to $628.1M, raising potential liquidity concerns despite strong 105.8% revenue growth.

The company is burning through cash at an accelerating rate, with operating cash outflows increasing significantly faster than revenue growth, suggesting operational inefficiencies or increased trial costs. The substantial decline in cash position combined with worsening cash flow metrics could create funding pressures within the next 12-18 months if the trend continues.

Comparing 2026-03-17 vs 2025-02-25View on EDGAR →
FINANCIAL ANALYSIS

While revenue more than doubled to $72.6M, this positive development was overshadowed by a dramatic 51.6% increase in operating cash burn to -$249.7M and R&D expenses growing 38.9% to $240.3M. The company's balance sheet contracted across all major categories, with cash declining 28.6% to $628.1M and total assets falling 25% to $717.6M, indicating significant cash consumption that outpaced revenue gains. This financial profile suggests BCYC is in an intensive cash-burning phase of clinical development that may require additional funding if current burn rates persist.

FINANCIAL STATEMENT CHANGES
Revenue
P&L
+105.8%
$35.3M→$72.6M

Strong top-line growth of 105.8% — accelerating demand or successful expansion into new markets.

Capital Expenditure
Cash Flow
+90.3%
$1.2M→$2.4M

Capital expenditure jumped 90.3% — major investment cycle underway; assess returns on deployment.

Operating Cash Flow
Cash Flow
-51.6%
-$164.7M→-$249.7M

Operating cash flow fell 51.6% — earnings quality concerns; investigate working capital changes and non-cash items.

R&D Expense
P&L
+38.9%
$173.0M→$240.3M

R&D investment increased 38.9% — signals commitment to future product development, though near-term margin impact.

Total Liabilities
Balance Sheet
-34.3%
$163.8M→$107.6M

Liabilities reduced 34.3% — deleveraging improves balance sheet strength and financial flexibility.

Net Income
P&L
-29.5%
-$169.0M→-$219.0M

Net income declined 29.5% — review whether driven by operations, interest costs, or non-recurring items.

Cash & Equivalents
Balance Sheet
-28.6%
$879.5M→$628.1M

Cash decreased 28.6% — monitor burn rate and upcoming capital needs.

Current Assets
Balance Sheet
-26.5%
$928.6M→$682.9M

Current assets declined 26.5% — monitor working capital adequacy and short-term liquidity.

Total Assets
Balance Sheet
-25%
$956.9M→$717.6M

Total assets contracted 25% — asset sales, write-downs, or balance sheet optimization underway.

Stockholders Equity
Balance Sheet
-23.1%
$793.1M→$610.0M

Equity decreased 23.1% — buybacks or losses reducing book value, monitor solvency ratios.

LANGUAGE CHANGES
NEW — 2026-03-17
PRIOR — 2025-02-25
ADDED
As of March 12, 2026, the registrant had 50,269,082 ordinary shares, nominal value 0.01 per share, and 19,437,944 non-voting ordinary shares, nominal value 0.01 per share, outstanding.
Our internal programs are focused on oncology indications with high unmet medical need.
Our product candidate, nuzefatide pevedotin, formerly BT5528, is a Bicycle Drug Conjugate, or a BDC molecule, whereby the Bicycle molecule is chemically attached to a toxin that, when administered, is cleaved from the Bicycle molecule and kills the tumor cells.
We are evaluating nuzefatide pevedotin, a BDC molecule targeting Ephrin type A receptor 2, or EphA2, in both an ongoing company-sponsored Phase I/II clinical trial to assess safety, pharmacokinetics and clinical activity in patients with advanced solid tumors and an ongoing company-sponsored Phase II clinical trial to evaluate the efficacy, safety and pharmacokinetics of nuzefatide pevedotin in adult patients with recurrent metastatic pancreatic ductal adenocarcinoma after progression on a first-line therapy, which commenced recruiting patients in the first quarter of 2026.
We are also developing BT1702, a Bicycle Radioconjugate, or BRC , molecule targeting Membrane Type 1 matrix metalloproteinase, or MT1-MMP, and carrying a lead-212, or 212 Pb, radioisotope payload for theranostic use.
+7 more — sign up free →
REMOVED
As of February 20, 2025, the registrant had 47,710,256 ordinary shares, nominal value 0.01 per share, and 21,492,099 non-voting ordinary shares, nominal value 0.01 per share, outstanding.
Our product candidates, zelenectide pevedotin, formerly BT8009, and BT5528, are each a Bicycle Toxin Conjugate, or a BTC molecule.
These Bicycle molecules are chemically attached to a toxin that, when administered, is cleaved from the Bicycle molecule and kills the tumor cells.
We are evaluating zelenectide pevedotin, a BTC molecule targeting Nectin-4, in both an ongoing company-sponsored Phase I/II clinical trial and an ongoing company-sponsored Phase II/III registrational trial called Duravelo-2, and enrollment in both of these trials are ongoing.
We are also evaluating BT5528, a BTC molecule targeting Ephrin type A receptor 2, or EphA2, in a company-sponsored Phase I/II clinical trial, for which enrollment is ongoing.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →